Welcome to our dedicated page for Verona Pharma plc news (Ticker: VRNA), a resource for investors and traders seeking the latest updates and insights on Verona Pharma plc stock.
Verona Pharma plc (VRNA) is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for respiratory diseases that have significant unmet medical needs. Headquartered in both the United States and the United Kingdom, Verona Pharma is publicly traded on the NASDAQ Global Market and the London Stock Exchange.
The company's flagship product, Ensifentrine, is currently in development for the treatment of chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF). Ensifentrine is a dual inhibitor that has demonstrated potential in reducing inflammation and relaxing airway muscles, addressing critical gaps in the treatment of these chronic diseases. In addition to COPD and CF, Verona Pharma aims to expand its therapeutic pipeline to include treatments for other respiratory conditions such as asthma.
Verona Pharma's success is underpinned by a team of seasoned experts with extensive backgrounds in the discovery, development, and commercialization of respiratory therapies. The company has also forged strong partnerships with leading research institutions and advocacy organizations in the respiratory health sector. These collaborations have been instrumental in advancing their clinical programs and have garnered Verona Pharma several awards for innovation.
Recent achievements include the successful completion of Phase 2 clinical trials for Ensifentrine, which showed promising results in improving lung function and reducing symptoms in COPD patients. The company is now steering towards Phase 3 trials, marking a significant milestone in its mission to bring effective treatments to market.
Financially, Verona Pharma has demonstrated stability and growth, strengthening its financial flexibility through strategic funding rounds. This robust financial health supports ongoing research and development activities, ensuring sustained progress in their clinical programs. The company’s near-term goals include advancing Ensifentrine into late-stage clinical trials and exploring potential marketing authorizations.
For the latest updates on Verona Pharma’s research, financial performance, and upcoming milestones, stay tuned to the latest news and press releases.
Verona Pharma (Nasdaq: VRNA) reported financial results for Q2 2021, highlighting continued progress in its Phase 3 ENHANCE clinical program for ensifentrine in treating COPD. Despite COVID-19 challenges, patient enrollment is on track with ENHANCE-2 at 63% and ENHANCE-1 at 70%. The company announced a strategic collaboration with Nuance Pharma valued at up to $219 million for developing ensifentrine in Greater China. Financially, cash and equivalents stood at $146 million, but R&D expenses surged to $20.6 million, leading to a net loss of $22.1 million.
Verona Pharma (Nasdaq: VRNA) has announced that David Zaccardelli, CEO, will present at three virtual investor conferences in August 2021. The conferences include the BTIG Virtual Biotechnology Conference on August 9, the Wedbush PacGrow Healthcare Virtual Conference on August 11, and the Canaccord Genuity Growth Conference on August 12. Verona Pharma is advancing ensifentrine, a product candidate for respiratory diseases, currently in clinical trials, which could be a first-ever therapy combining bronchodilator and anti-inflammatory effects.
Verona Pharma (Nasdaq: VRNA) will report its financial results for the second quarter and the first half of 2021 on August 5, 2021. The company plans to host a conference call at 8:30 a.m. EDT to discuss the results and provide a corporate update. Verona Pharma focuses on developing innovative therapies for respiratory diseases, with its leading candidate, ensifentrine, currently in Phase 3 trials for COPD. Ensifentrine aims to combine bronchodilator and anti-inflammatory properties in a single treatment.
Verona Pharma has partnered with Nuance Pharma to develop and commercialize ensifentrine in Greater China. The agreement includes a $40 million upfront payment ($25 million cash, $15 million in equity) along with potential milestone payments up to $179 million and tiered royalties on net sales. Nuance Pharma will cover all development costs. Ensifentrine targets chronic obstructive pulmonary disease (COPD) and has shown promising results in clinical trials, offering both bronchodilator and anti-inflammatory effects.
Verona Pharma (Nasdaq: VRNA), a clinical-stage biopharmaceutical company, will have its CEO, David Zaccardelli, present an overview at the Jefferies Virtual Healthcare Conference on June 1, 2021, at 9:00 AM ET. The event offers a significant platform for discussing the company's progress, particularly its innovative therapy, ensifentrine, aimed at treating respiratory diseases. A webcast of the presentation will be accessible on the company's website for 90 days following the event.
Verona Pharma (Nasdaq: VRNA) announced the acceptance of three abstracts related to ensifentrine at the American Thoracic Society International Conference 2021. These abstracts focus on its efficacy and safety profile in patients with chronic obstructive pulmonary disease (COPD). The Phase 2b studies demonstrate that ensifentrine significantly improves lung function and quality of life, regardless of the severity of COPD. Safety analyses indicate a profile similar to placebo for both gastrointestinal and cardiovascular effects. Ensifentrine is being developed as a dual-action treatment for respiratory diseases.
Verona Pharma (Nasdaq: VRNA) reported its Q1 2021 financial results and provided an update on its Phase 3 ENHANCE clinical program for ensifentrine in COPD. The company continues to expect enrollment completion by H2 2021 and plans to announce top-line data in 2022. Financially, the company's cash position was $169.6 million, down from $188.0 million in Q4 2020. R&D expenses rose to $13.6 million from $7.6 million, and G&A expenses increased to $9.3 million from $6.9 million. The net loss for Q1 2021 was $21.3 million compared to $12.3 million in Q1 2020.
Verona Pharma (Nasdaq: VRNA) announced significant results from a Phase 2b trial of nebulized ensifentrine in patients with symptomatic COPD, published in the International Journal of Chronic Obstructive Pulmonary Disease. The 4-week study of 416 patients showed clinically and statistically significant dose-dependent improvements in lung function and quality of life when ensifentrine was added to tiotropium maintenance therapy. Ensifentrine, a dual inhibitor of PDE3 and PDE4, demonstrated a favorable safety profile, comparable to placebo.
Verona Pharma plc (Nasdaq: VRNA) announced findings from a pilot study on ensifentrine, a treatment for COVID-19. Conducted on 45 hospitalized patients, the study revealed ensifentrine was safe but did not demonstrate clinical efficacy when added to standard care. One patient death occurred in the ensifentrine group. Despite this, recovery rates were reportedly better than expected. Ensifentrine is currently in Phase 3 development for COPD, showing promise in improving lung function and reducing symptoms in earlier studies. The company is focused on respiratory diseases with unmet medical needs.
Verona Pharma (Nasdaq: VRNA) will release its financial results for Q1 2021 on April 29, 2021. A conference call is scheduled for 9:00 a.m. EDT featuring a corporate update. The company is focused on developing ensifentrine, a potential first-in-class therapy for respiratory diseases, currently in a Phase 3 program for COPD. Additional formulations are in Phase 2 trials. The company is also evaluating ensifentrine's use in COVID-19 and other respiratory conditions. Further details can be found on their website.
FAQ
What is the current stock price of Verona Pharma plc (VRNA)?
What is the market cap of Verona Pharma plc (VRNA)?
What is Verona Pharma plc?
What is Ensifentrine?
What diseases does Verona Pharma target?
Where is Verona Pharma listed?
Who leads Verona Pharma?
What recent achievements has Verona Pharma made?
What are Verona Pharma’s near-term milestones?
Does Verona Pharma have any partnerships?
What awards has Verona Pharma received?
How can I stay updated on Verona Pharma?
